SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 862-867. Prepublished online as a Blood First Edition Paper on October 19, 2006; DOI 10.1182/blood-2006-07-028829. This Article Full Text Full Text (PDF) Supplemental Table All Versions of this Article: blood-2006-07-028829v1 109/3/862    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chan, R. J. Articles by Feng, G.-S. Search for Related Content PubMed PubMed Citation Articles by Chan, R. J. Articles by Feng, G.-S. Related Collections Neoplasia Oncogenes and Tumor Suppressors Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLE PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase Rebecca J. Chan1, and Gen-Sheng Feng2,3 1 Department of Pediatrics, the Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis; 2 Programs in Signal Transduction and Stem Cells & Regeneration, Burnham Institute for Medical Research, La Jolla, CA; 3 Institute for Biomedical Research, Xiamen University, Xiamen, China Elucidation of the molecular mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes. One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homology 2 (SH2) domains (Shp2). This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis. More recently, somatic missense PTPN11 gain-of-function mutations have been detected in leukemias and rarely in solid tumors, and have been found to induce aberrant hyperactivation of the Ras-Erk pathway. This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the molecular mechanisms underlying cell transformation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C.-H. Yeang, F. McCormick, and A. Levine Combinatorial patterns of somatic gene mutations in cancer FASEB J, August 1, 2008; 22(8): 2605 - 2622. [Abstract] [Full Text] [PDF] S. Martinelli, P. Torreri, M. Tinti, L. Stella, G. Bocchinfuso, E. Flex, A. Grottesi, M. Ceccarini, A. Palleschi, G. Cesareni, et al. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes Hum. Mol. Genet., July 1, 2008; 17(13): 2018 - 2029. [Abstract] [Full Text] [PDF] H.-H. Lee and Z.-F. Chang Regulation of RhoA-dependent ROCKII activation by Shp2 J. Cell Biol., June 16, 2008; 181(6): 999 - 1012. [Abstract] [Full Text] [PDF] C. H. Ha, A. M. Bennett, and Z.-G. Jin A Novel Role of Vascular Endothelial Cadherin in Modulating c-Src Activation and Downstream Signaling of Vascular Endothelial Growth Factor J. Biol. Chem., March 14, 2008; 283(11): 7261 - 7270. [Abstract] [Full Text] [PDF] Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL J. Biol. Chem., December 14, 2007; 282(50): 36463 - 36473. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020